Carmell Therapeutics Corporation Cash Flow Conversion Efficiency
Carmell Therapeutics Corporation cash flow conversion efficiency. Based on the latest financial reports, Carmell Therapeutics Corporation (CTCX) has a cash flow conversion efficiency ratio of 0.198x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-752.95K) by net assets ($-3.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Carmell Therapeutics Corporation (2021–2024)
Cash flow conversion efficiency of Carmell Therapeutics Corporation from 2021 to 2024. This chart illustrates how Carmell Therapeutics Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CTCX stock price and chart for real-time trading data and today's change.
Carmell Therapeutics Corporation Cash Flow Conversion Ratio Explained
Carmell Therapeutics Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Carmell Therapeutics Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carmell Therapeutics Corporation ranked by their cash flow conversion efficiency. Also see CTCX market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UNITH LTD.
F:CM30
|
N/A |
|
CARLSON INV. ZY 13
F:2HB
|
-0.001x |
|
Strategem Capital Corp
V:SGE
|
0.008x |
|
Traws Pharma Inc
NASDAQ:TRAW
|
-4.438x |
|
Kane Biotech Inc
V:KNE
|
0.912x |
|
Resources & Energy Group Ltd
AU:REZ
|
-0.115x |
|
OLB Group Inc
NASDAQ:OLB
|
-0.148x |
|
Acurx Pharmaceuticals LLC
NASDAQ:ACXP
|
-0.210x |
Annual Cash Flow Conversion Efficiency for Carmell Therapeutics Corporation (2021–2024)
The table below shows the annual cash flow conversion efficiency of Carmell Therapeutics Corporation from 2021 to 2024. Review Carmell Therapeutics Corporation financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.71 Million | $-4.39 Million | 0.931x | +376.10% |
| 2023-12-31 | $24.75 Million | $-8.35 Million | -0.337x | -471.78% |
| 2022-12-31 | $-37.79 Million | $-3.43 Million | 0.091x | +128.03% |
| 2021-12-31 | $-29.58 Million | $-1.18 Million | 0.040x | -- |
About Carmell Therapeutics Corporation
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on … Read more